- Home
- CAI vs EMN Comparison
CAI vs EMN Comparison
Compare CAI & EMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAI | EMN |
|---|---|---|
| Founded | 2008 | 1920 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 8.3B |
| IPO Year | 2025 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CAI | EMN |
|---|---|---|
| Price | $32.13 | $65.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 17 |
| Target Price | $32.08 | ★ $75.06 |
| AVG Volume (30 Days) | ★ 3.4M | 1.3M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 5.17% |
| EPS Growth | ★ 69.79 | N/A |
| EPS | N/A | ★ 2.51 |
| Revenue | $812,033,000.00 | ★ $8,752,000,000.00 |
| Revenue This Year | $26.78 | $5.62 |
| Revenue Next Year | $19.27 | $1.84 |
| P/E Ratio | ★ N/A | $25.84 |
| Revenue Growth | ★ 96.97 | N/A |
| 52 Week Low | $14.19 | $56.11 |
| 52 Week High | $32.89 | $83.47 |
Technical Indicators
Market Signals| Indicator | CAI | EMN |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 55.19 |
| Support Level | $16.52 | $65.72 |
| Resistance Level | $32.73 | $67.62 |
| Average True Range (ATR) | 1.80 | 1.48 |
| MACD | 0.07 | 0.52 |
| Stochastic Oscillator | 92.15 | 95.57 |
Price Performance
Historical ComparisonAbout CAI Caris Life Sciences Inc.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
About EMN Eastman Chemical Company
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.